Market Overview

Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot

Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot
Related MYL
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
9 Policy Catalysts For Health Care Investors To Watch Before Year's End
Senate Dems introduce bill to block "excessive" increases in drug prices (Seeking Alpha)

After two years on the sidelines, Morgan Stanley is taking a more bullish bet on Mylan NV (NASDAQ: MYL). A Tuesday upgrade boosted Mylan's ratings ratio to 13 Buys and seven Holds.

The Rating

Analyst David Risinger raised Mylan from Equal-weight to Overweight and increased the price target from $39 to $50.

The Thesis

Notably, Mylan is now Morgan Stanley’s only Overweight generic drugs stock.

The company recently received regulatory approval for the first of 18 biosimilar candidates, and Risinger said he anticipates increasing market enthusiasm for the pipeline.

“We view Mylan as the best-positioned U.S. generics company to capitalize on biosimilars via its industry-leading partnerships with Biocon and Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA),” Risinger said in a Tuesday note “Biosimilars are often high value, limited competition opportunities.”

The rest of the firm’s portfolio compares favorably with those of peers, and Risinger said he sees opportunity to gain U.S. generics market share as competitors endure instability.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) is restructuring and reducing its workforce; Sandoz Inc is selling its oral generics unit; and Apotex Inc is suffering leadership challenges, according to Morgan Stanley. 

Amid these circumstances, Risinger said he Mylan’s stock growth to accelerate from 12 percent to 24 percent in the second half of 2018, driven in part by the potential approval of generic Advair and biosimilar Neulasta.

Price Action

Mylan shares were up more than 5 percent at $43.64 in Tuesday morning trading. 

Related Links:

Teva Vs Mylan: Wells Fargo Weighs In

Mylan Sharply Lower Amid Drug Price Fixing Concerns

Latest Ratings for MYL

Nov 2018ArgusUpgradesHoldBuy
Nov 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Nov 2018RBC CapitalMaintainsOutperformOutperform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: David RisingerAnalyst Color Upgrades Health Care Price Target Top Stories Analyst Ratings General Best of Benzinga


Related Articles (MNTA + MYL)

View Comments and Join the Discussion!

Latest Ratings

SYBXChardan CapitalInitiates Coverage On20.0
GEJP MorganUpgrades6.0
FEYEMorgan StanleyDowngrades21.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Think Again About ExxonMobile

This Day In Market History: Dow Hits 2009 Financial Crisis Low